Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

Company Overview

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Key Stats

• Today's Range: $298.00 to $308.52
• 50-Day Range: $267.56 to $348.73
• 52-Week Range: $200.63 to $377.46
• Volume: 236,785 shs
• Average Volume: 359,418 shs
• Market Capitalization: $6.71 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $420.63
• Consensus Rating: Moderate Buy

Madrigal Pharmaceuticals Stock Analysis - MarketRank™

Madrigal Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 133rd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Madrigal Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($23.47) to ($12.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Madrigal Pharmaceuticals is -16.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Madrigal Pharmaceuticals is -16.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Madrigal Pharmaceuticals has a P/B Ratio of 8.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.07% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Madrigal Pharmaceuticals has recently decreased by 4.53%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Madrigal Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Madrigal Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.92

Percentage of Shares Shorted

17.07% of the outstanding shares of Madrigal Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Madrigal Pharmaceuticals has recently decreased by 4.53%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.87

News Sentiment

Madrigal Pharmaceuticals has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Madrigal Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

Only 2 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,316,969.00 in company stock.

Percentage Held by Insiders

21.50% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MDGL Stock Analysis - Frequently Asked Questions

How have MDGL shares performed this year?

Madrigal Pharmaceuticals' stock was trading at $308.57 at the beginning of 2025. Since then, MDGL stock has decreased by 2.1% and is now trading at $302.17.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its earnings results on Thursday, May, 1st. The biopharmaceutical company reported ($3.32) EPS for the quarter, beating the consensus estimate of ($3.62) by $0.30. The biopharmaceutical company earned $137.25 million during the quarter, compared to the consensus estimate of $112.79 million. Madrigal Pharmaceuticals had a negative trailing twelve-month return on equity of 50.54% and a negative net margin of 123.38%.
Read the conference call transcript.

Who are Madrigal Pharmaceuticals' major shareholders?

Top institutional shareholders of Madrigal Pharmaceuticals include William Blair Investment Management LLC (1.58%), Mirae Asset Global Investments Co. Ltd. (0.32%), TD Asset Management Inc (0.10%) and Envestnet Asset Management Inc. (0.07%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, Paul A Friedman, William John Sibold, Brian Joseph Lynch, Richard S Levy, Fred B Craves, Carole Huntsman, Shannon T Kelley, Robert E Waltermire, James M Daly and Remy Sukhija.
View institutional ownership trends.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MDGL
• CIK: 1157601
• Web: www.madrigalpharma.com
• Phone: (267) 824-2827
• Fax: 781-274-8228
• Employees: 90
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Madrigal Pharmaceuticals: $420.63
• High Price Target: $469.00
• Low Price Target: $350.00
• Potential Upside/Downside: +39.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($18.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$465.89 million
• Net Margins: -123.38%
• Pretax Margin: -123.38%
• Return on Equity: -50.54%
• Return on Assets: -37.19%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 5.91
• Quick Ratio: 5.58

Sales & Book Value

• Annual Sales: $180.13 million
• Price / Sales: 37.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $34.59 per share
• Price / Book: 8.74

Miscellaneous

• Outstanding Shares: 22,200,000
• Free Float: 17,429,000
• Market Cap: $6.71 billion
• Optionable: Optionable
• Beta: -1.02